GlassScriptPhysician profile
Radona E George
NPI 1861851750
$2,411.33
in general payments reported to CMS, 2019-2025
10 companies · $1,372 in 2025
The $1,372 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $87.26 · 2023: $363 · 2024: $589 · 2025: $1,372.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,324.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,324.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $1,071.36 | 2022-2025 | Apretude, Dovato, Cabenuva |
| Gilead Sciences, INC. | $993.17 | 2023-2025 | Biktarvy |
| Janssen Pharmaceuticals, INC | $121.78 | 2022-2025 | Spravato |
| Napo Pharmaceuticals INC | $91.25 | 2023-2025 | Mytesi |
| Pfizer INC. | $35.48 | 2024-2025 | |
| Emd Serono, INC. | $31.77 | 2022 | |
| Abbvie INC. | $19.19 | 2025 | |
| Janssen Biotech, INC. | $17.22 | 2023 | Symtuza |
| Astellas Pharma US INC | $15.11 | 2024 | Veozah |
| Takeda Pharmaceuticals U.S.A., INC. | $15.00 | 2023 | Vpriv |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Radona George listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.